Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06876649 · ClinicalTrials.gov registry record · Phase 4
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
A Phase 4 study of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 787
- Enrollment target
- 20
- Study locations
NCT06876649: Recruiting Phase 4 study of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma, sponsored by Eli Lilly and Company.
NCT06876649 is a Phase 4 study of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 787 participants, above the 178-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (342% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06876649, a Phase 4 study of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 787 participants
- Enrollment target
- 20
- Study locations
Study Summary
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.
Conditions Studied
Interventions
- DRUG Pirtobrutinib
Study Locations (20)
New York
- Cayuga Cancer Center - Ithaca
- Northwell Health - Lake Success
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - New York
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - New York
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - New York
Florida
- Cancer Specialists, LLC - Jacksonville
- Sylvester Comprehensive Cancer Center - Miami
- Florida Cancer Specialists - Sarasota
Georgia
- The Emory Clinic - Atlanta
Illinois
- Northwestern University - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic- Minnesota - Rochester
Nebraska
- University Of Nebraska Medical Center - Omaha
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 787 participants |
| Start Date | 2025-05-20 |
| Est. Completion | 2032-12 |
| Phase | Phase 4 |
What NCT06876649 shows while recruiting
NCT06876649 is an interventional study that assigns participants to a tested intervention. The registered 787 participants enrollment target is mid-sized for trials with a published cap, above the 178-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (342% higher).
The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Pirtobrutinib is the first listed.
NCT06876649 names 20 study sites across 14 states, led by New York, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06876649 about?
NCT06876649 is a clinical study titled "A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib". The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies...
What is the current status of trial NCT06876649?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 787 participants. The study started on 2025-05-20. Estimated completion is 2032-12.
What conditions does trial NCT06876649 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT06876649?
The interventions under investigation include: Pirtobrutinib (DRUG).
Who is sponsoring clinical trial NCT06876649?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06876649 being conducted?
This trial has 20 study locations across Florida, Georgia, Illinois, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06876649's enrollment target sits among peer trials
787 7th of 187 higher than 181 of 187 other Chronic Lymphocytic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
RECRUITING · Phase 4
-
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 2
-
In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
RECRUITING
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06488781 · 787 participants · Phase 2
Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0
- NCT07276724 · 786 participants · Phase 3
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
- NCT07359846 · 786 participants · Phase 3
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
- NCT06498128 · 785 participants
Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI